MARLBOROUGH, Mass.,
May 2, 2016 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics in dermatology and
ophthalmology that address significant unmet medical needs,
announced today that it has been granted a patent from the European
Patent Office (EPO) for the composition of matter for its
self-delivering RNAi platform (sd-rxRNA®). The Patent (EP 2 340 310
B1), titled "Reduced Size Self-Delivering RNAi Compounds" broadly
covers the composition of RXi's sd-rxRNA platform and is not
scheduled to expire until 2029.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"We are pleased that our novel platform has been recognized with
the granting of this patent by the European Patent Office," said
Dr. Geert Cauwenbergh, President and
CEO of RXi Pharmaceuticals. He added that, "The issuance of this
patent not only expands and strengthens our intellectual property
estate, it further increases the value proposition of both our
Dermatology and Ophthalmology Franchises and positions the Company
better for numerous strategic partnering opportunities."
About RXi's Intellectual Property Estate
The Company has been diligent and proactive with its approach to
broadly protect its valuable corporate assets by securing patent
protection for its RNAi platform and immunotherapy agent,
Samcyprone™. Our RNAi portfolio currently includes 73 issued
patents broadly covering the composition and methods of use of our
self-delivering platform technology as well as uses of our
sd-rxRNAs targeting CTGF for the treatment of fibrotic
disorders. These patents cover RXI-109 for the treatment of
dermal and ocular fibrosis, new RNAi compounds and their use as
therapeutics and/or cosmetics, chemical modifications of RNAi
compounds that improve the compounds' suitability for therapeutic
uses (including delivery) and compounds directed to specific
targets (i.e., that address specific disease states).
The Samcyprone™ portfolio includes one issued patent and three
patent applications. The patent and patent applications cover both
the compositions and methods of use of Samcyprone™ for the
treatment of warts, human papilloma virus (HPV) skin infections,
skin cancer (including melanoma) and immunocompromised
patients.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage RNAi company developing innovative therapeutics in
dermatology and ophthalmology that address significant unmet
medical needs. Building on the pioneering work of RXi's
Scientific Advisory Board Chairman and Nobel Laureate Dr.
Craig Mello, our discovery and
clinical development programs are based on our proprietary RNAi
(sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our
clinical development programs include RXI-109, an sd-rxRNA, for the
treatment of dermal and ocular scarring, and Samcyprone™ for the
treatment of such disorders as warts, alopecia areata,
non-malignant skin tumors and cutaneous metastases of
melanoma. RXi's robust pipeline, coupled with an extensive
patent portfolio, provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas. We are committed to being a partner of choice for academia,
small companies, and large multinationals. We welcome ideas and
proposals for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-secures-european-patent-for-novel-rnai-platform-300260656.html
SOURCE RXi Pharmaceuticals Corporation